メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
富山大学 ホーム
日本語
English
ホーム
プロファイル
研究部門
プロジェクト
研究成果
データセット
受賞
活動
コース
専門知識、名前、または所属機関で検索
Scopus著者プロファイル
長田 巧平
助教
内科学（第三）講座
h-index
197
被引用数
5
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
2013
2019
年別の研究成果
概要
フィンガープリント
ネットワーク
研究成果
(5)
類似のプロファイル
(4)
フィンガープリント
Kohei Nagataが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Keyphrases
Sorafenib
100%
Liver
58%
Advanced Hepatocellular Carcinoma
58%
Pathological Features
50%
Hyperbilirubinemia
50%
Immune-related Adverse Events
50%
Metastatic Lesions
50%
Expression Features
50%
Glossopharyngeal Neuralgia
50%
Nontransplant
50%
Metallothionein Expression
50%
Combined Hepatocellular-cholangiocarcinoma
50%
On Demand
50%
Pancreatitis
50%
Combination Therapy
50%
Sinusoidal Obstruction Syndrome
50%
Transaminitis
50%
Esophageal Squamous Cell Carcinoma
50%
Cadmium
50%
Acute Pancreatitis
50%
Intrahepatic Bile Duct
50%
Daclatasvir
50%
Asunaprevir
50%
Syncope
50%
Rectal Neuroendocrine Tumor
50%
Chemotherapy
50%
Pancreatic Arteriovenous Malformation
50%
Non-Hodgkin Lymphoma
50%
Bile Duct Injury
50%
Immune Checkpoint Inhibitor Treatment
50%
Itai-itai Disease
50%
Combined Therapy
50%
Cadmium Poisoning
50%
Direct-acting Antivirals
45%
Arteriovenous Malformation
37%
Metastasis
33%
Older Men
33%
Cancer Cells
25%
Pathological Findings
25%
Gallbladder Cancer
25%
Noma
25%
Hematopoietic Stem Cell Transplantation
25%
Acute Cholecystitis
25%
Cholecystoscopy
25%
Percutaneous Transhepatic Gallbladder Drainage (PTGBD)
25%
Monotherapy
25%
Oncogene
25%
Pancreas
25%
Gallbladder
25%
Cancer Therapeutic Target
25%
Medicine and Dentistry
Recurrent Disease
85%
Chemotherapy
69%
Combined Therapy
50%
Arteriovenous Malformation
50%
Elevated Transaminases
50%
Hyperbilirubinemia
50%
Immune-Related Adverse Events
50%
Immune Checkpoint Inhibitor
50%
Glossopharyngeal Neuralgia
50%
Neuroendocrine Tumor
50%
Esophageal Squamous Cell Carcinoma
50%
Non-Hodgkin Lymphoma
50%
Acute Pancreatitis
50%
Liver Venoocclusive Disease
50%
Bile Duct Injury
50%
Intrahepatic Bile Duct
50%
Transplantation
50%
Daclatasvir
50%
Asunaprevir
50%
Faintness
50%
Pancreatitis
40%
Liver Cirrhosis
37%
Antivirus Agent
37%
Surgery
32%
Percutaneous Transhepatic Drainage
25%
Acute Cholecystitis
25%
Hematopoietic Stem Cell Transplantation
25%
Biopsy Technique
25%
Gallbladder Cancer
25%
Adenocarcinoma
25%
Hepatectomy
22%
Metastatic Carcinoma
20%
Hematoma
20%
Pancreatic Duct
20%
Steroid Treatment
20%
Neoplasm
18%
Esophagus Carcinoma
16%
Tumor Marker
12%
Chronic Hepatitis C
12%
Gastrectomy
12%
Embolization
12%
Cytotechnology
12%
Diagnostic Procedure
12%
Reoperation
12%
Polyethylene Terephthalate
12%
Liver Disease
12%
Puncture
12%
Bile
12%
Gastrointestinal Tract
12%
Extrahepatic Bile Duct
12%
Pharmacology, Toxicology and Pharmaceutical Science
Sorafenib
100%
Chemotherapy
89%
Recurrent Disease
60%
Liver Cell Carcinoma
57%
Esophageal Squamous Cell Carcinoma
50%
Hyperbilirubinemia
50%
Combination Therapy
50%
Glossopharyngeal Neuralgia
50%
Bile Duct Carcinoma
50%
Cadmium Poisoning
50%
Itai-Itai Disease
50%
Metallothionein
50%
Nonhodgkin Lymphoma
50%
Neuroendocrine Tumor
50%
Hypertransaminasemia
50%
Liver Venoocclusive Disease
50%
Asunaprevir
50%
Daclatasvir
50%
Faintness
50%
Antivirus Agent
44%
Liver Cirrhosis
44%
Hepatotoxicity
28%
Neoplasm
28%
Monotherapy
25%
Stomatitis
21%
Esophagus Carcinoma
16%
Hepatitis C Virus
14%
Fibrosis
14%
Long Term Exposure
14%
Side Effect
12%
Tolerability
12%
Overall Survival
12%
Liver Cancer
12%
Hepatitis B
12%
Chronic Hepatitis C
12%
Disease
12%
Alanine Aminotransferase
12%
Liver Disease
12%
Deterioration
12%
Progression Free Survival
12%
Liver Metastasis
10%
Liver Injury
8%
Base
8%
Obstruction
8%
Chemotherapy Regimens
8%
Electric Shock
8%
Chemoradiation Therapy
8%
Heavy Metal
7%
Fluorodeoxyglucose
7%
Phosphotransferase Inhibitor
7%
